Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Post by CoffeeBeanson Aug 18, 2021 12:57pm
237 Views
Post# 33724001

Not a Scientist but...

Not a Scientist but...

I am not a scientist and I would assume the vast majority of people on the site aren't either. So this drug is still in phase 2 trials. They've had many different trials And have come across a stumbling block in their last one. 7% And have come across a stumbling block in their last one. 7% had very high (500%) so this was only a handful of people so there must be a reason and they are looking for that reason. When you look at other Drugs like Tylenol and Advil taking those drugs produce Elevated liver enzymes in 15% of all users. And let's not forget that Tylenol and Advil had issues during their development along the way and the ANTIBE drug is only in phase 2 and will figure this out. 

I've been holding for over four years when this stock was eight pennies. I have lowered my stock expectations but I do expect it to rebound in the next 18 months. 

To all the scientists and Penny flippers out there, he would be better to buy at this price and forget about the stock been trying to make enough money to buy a pizza every time it drops. 

 

<< Previous
Bullboard Posts
Next >>